FAP and neoplasm: In another first-in-human study in patients with advanced adenocarcinoma (pancreatic, breast, rectal, and ovarian), 177Lu-FAP-2286 showed prolonged tumor retention and high tumor absorbed doses, with low systemic exposure and manageable grade 3 adverse events [189].